AURA
NASDAQ · Biotechnology
Aura Biosciences Inc
$7.01
-0.10 (-1.41%)
Open$7.01
Previous Close$7.11
Day High$7.09
Day Low$6.85
52W High$9.54
52W Low$4.73
Volume—
Avg Volume367.8K
Market Cap826.46M
P/E Ratio—
EPS$-1.74
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+363.1% upside
Current
$7.01
$7.01
Target
$32.46
$32.46
$26.53
$32.46 avg
$55.40
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 444.35M | 423.64M | 422.21M |
| Net Income | 17.80M | 13.08M | 16.40M |
| Profit Margin | 4.0% | 3.1% | 3.9% |
| EBITDA | 20.20M | 21.97M | 19.97M |
| Free Cash Flow | 12.95M | 9.01M | 11.94M |
| Rev Growth | +9.8% | +0.1% | +6.7% |
| Debt/Equity | 1.09 | 1.02 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |